ASX:NRT
NASDAQ:NVGN

Novogen Ltd
(Company)

ABN 37 063 259 754

Capital Structure

Ordinary Shares on issue:

429 M

Board of Directors

Mr John O'Connor
Chairman
Non-Executive Director

Mr Bryce Carmine
Deputy Chairman
Non-Executive Director

Dr James Garner
Chief Executive Officer
Managing Director

Mr Ian Phillips MNZM
Non-Executive Director

Mr Iain Ross
Non-Executive Director

Mr Steven Coffey
Non-Executive Director

MARKET RELEASE
12 September 2016

NOVOGEN PRESENTS AT RODMAN & RENSHAW CONFERENCE

Sydney, 12th September 2016 – Australian oncology-focused biotechnology company Novogen Ltd (ASX: NRT; NASDAQ: NVGN) is pleased to release the presentation that CEO, Dr James Garner will be presenting at the Rodman & Renshaw 18th Annual Global Investment Conference being held in New York.

Dr James Garner will be presenting in New York at the Lotte New York Palace Hotel on Monday 12 September at 9:10 am, EDT.

[ENDS]

Media and Investor Relations	Investor Relations (US)
Glen Zurcher E: glen.zurcher@irdepartment.com.au T: +61 420 249 299	Robert Kennedy E: robert.kennedy@novogen.com T: +1 212 519 9832 / +1 646 662 3574

About Novogen Limited

Novogen Limited (ASX: NRT; NASDAQ: NVGN) is an oncology-focused biotechnology company based in Sydney, Australia. Novogen has two proprietary drug discovery platforms (superbenzopyrans and anti-tropomyosins) with the potential to yield first-in-class agents across a range of oncology indications. The three lead molecules Cantrixil, Anisina, and Trilexium are in preclinical development, with the most advanced molecule, Cantrixil, slated to enter clinical trials in late 2016. For more information, please visit: www.novogen.com

Novogen Limited

Presentation to Rodman & Renshaw
18th Annual Global Investment Conference

Dr James Garner
Chief Executive Officer
james.garner@novogen.com

New York, NY

12 September 2016

Version 2.4

Forward-Looking Statements

This presentation contains “forward-looking statements” within the meaning of the “safe-harbor” provisions of the Private Securities Litigation Reform Act of 1995. Such statements involve known and unknown risks, uncertainties and other factors that could cause the actual results of the Company to differ materially from the results expressed or implied by such statements, including changes from anticipated levels of customer acceptance of existing and new products and services and other factors. Accordingly, although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company has no obligation to sales, future international, national or regional economic and competitive conditions, changes in relationships with customers, access to capital, difficulties in developing and marketing new products and services, marketing existing products and services update the forward-looking information contained in this presentation.

Novogen is a biotech company dedicated to driving sustainable, long-term growth in shareholder value



Focus on unmet medical need

Pipeline of novel therapies, targeting oncology patients poorly served by existing treatment options

Financially sound

Listed on ASX and NASDAQ, with cash runway sufficient to drive existing pipeline for at least two years

Clinical stage

Lead molecule entering phase I in Q4 2016, with substantial flow of value-driving milestones over 12-18 months

Strong management and Board

Lean team of internationally-experienced pharma executives, overseen by seasoned Board

Novogen is listed on ASX and NASDAQ (via ADRs) and is well-funded for current operations

Market Capitalisation	US$ 31 million
Listing	ASX: NRT NASDAQ: NVGN (1:25 ratio)
Average Daily Volume	ASX: ~570,000 /day NASDAQ: ~50,000 ADRs /day
Shares on Issue	430 million (40% US, 60% Australia)
Outstanding Options / Warrants	74 million

Cash at Bank
US$ 25 million

Novogen is oncology-focused, with a robust in-house pipeline and strong partnering aspirations



Novogen is configured for efficient and effective drug development

2015	2016
Early-stage, discovery-focused biotech with mixed portfolio of projects and limited clarity in path to value generation	Clinical-stage, development-focused biotech, dedicated to oncology, and highly focused on value generation

- Rationalisation of portfolio to focus on three most advanced oncology opportunities; deprioritization of early stage rare diseases program
- Addition of internationally-experienced pharma executives to team
- Establishment of Scientific Advisory Board
- Development of rigorous GxP quality systems
- Rationalisation of corporate structure and governance

Novogen anticipates a rich news flow of value-driving events over the next 12-18 months

Key Milestones		
1Q 2016	Granting of patent for SBP technology	✓
2Q 2016	Granting of patent for ATM technology	✓
3Q 2016	Submission of IND for Cantrixil	✓
4Q 2016	Start of phase I trial for Cantrixil	
2017	Submission of IND for Anisina	
2017	Start of phase I trial for Anisina	

Novogen has a strong management team with international experience in big pharma

Dr James Garner
Chief Executive Officer & Managing Director

Physician / MBA; Extensive pharma drug development experience

Dr David Brown
Chief Scientific Officer

Twenty years of drug discovery and development experience

Dr Gordon Hirsch
Chief Medical Officer

Physician / MBA; Twenty years of pharmaceutical industry experience

Dr Peng Leong
Chief Business Officer

Eighteen years of business development and investment banking experience

Dr Andrew Heaton
VP, Drug Discovery

Twenty years of medicinal chemistry experience

Cristyn Humphreys
Chief Financial Officer

Chartered accountant with twenty years of experience in corporate roles

NOVOGEN

Novogen's pipeline includes three molecules, with two entering the clinic over next nine months

ATM Platform	First-in-class program targeting cancer-specific tropomyosin isoform in cytoskeletal microfilaments of cancer cells, leading to apoptosis
SBP Platform	First-in-class program based on earlier clinically-validated isoflavone chemotype (e.g. phenoxidiol, MEI Pharma), but with distinct IP space and greater preclinical activity



Cantrixil™ (TRXE-002-1)

SBP

First-in-class agent that degrades the 'tumor-initiating cells' thought responsible for tumor recurrence after chemotherapy

Most chemotherapy agents considered more active against rapidly-dividing tumor cells, but less active against slower-dividing 'tumor-initiating cells'



Cantrixil believed to also reduce tumor-initiating cells and thereby slow recurrence

Single agent activity in PDX models of ovarian cancer

Treated animals showed reduction in tumor volume with Cantrixil treatment



Yale | *Data courtesy of Prof Gil Mor, Yale University*

NOVOGEN

Cantrixil is entering a phase I clinical trial in 4Q 2016 in ovarian cancer

High Incidence



Ovarian Cancer

- 17th most common tumour worldwide
- 7th most common tumour in women
- ~240,000 new cases per annum
- 1.7% of all new cancer cases
- Overall lifetime risk is 1.6% for women
- Genetic cause (BRCA1 or BRCA2) in ~10% of cases
- More common in women who have not borne children
- 80% of cases occurring in women >50 years of age

Poor Prognosis with Existing Therapies



Growing and Evolving Market



Source: GLOBOCAN; Holschneider & Berek (2000), *Sem Surg Onc* 19(1):3-10; Decision Resources

Anisina™ (ATM-3507)

ATM

First-in-class agent that targets microfilaments, thereby enhancing activity of microtubule-targeting chemotherapy

Cancer cell cytoskeleton has two main components: microtubules and microfilaments. Microtubules are well-established targets for chemotherapy

Tumor Cell

— *microtubules*
— *microfilaments*

Chemotherapy



Microfilaments are unaffected

Chemo + Anisina



Cell structure collapses

Anisina believed to combine synergistically with microtubule-targeting chemo

Preclinical evidence of synergy with chemo

Anisina increases sensitivity of cancer cells to vinca alkaloids by ~30x



Data courtesy of Dr Tim Cripe, Nationwide Children's Hospital


NOVOGEN